Combined LDH Albumin Score (CLAS) and Neutrophil Lymphocyte Ratio (NLR) are Predictive for Survival Patients with Metastatic Non-Small Cell Carcinoma Treated with Nivolumab as Monotherapy
Elif Sahin11Department of Medical Oncology, Kocaeli City Hospital, Kocaeli, Türkiye
Objectives: It was aimed to investigate the prognostic significance of neutrophil-to-lymphocyte ratio(NLR), plateletto-lymphocyte ratio(PLR), systemic immune-inflammation index(SII), and Combined LDH Albumine Score(CLAS) in metastatic non-small cell lung cancer(mNSCLC) patients receiving nivolumab. Methods: Sixty-five mNSCLC patients who received nivolumab as monotherapy and had a follow-up file in Kocaeli City Hospital were analyzed retrospectively. ROC-curve analysis and median values were used to determine the cut-off. The relationship between overall survival(OS), progression-free survival(PFS) and clinical and laboratory parameters was evaluated by multivariate analyses. Results: Mean age was 62.5±4.5 years, more than half(66%) had denovo metastatic disease. Median follow-up time was 22 (IQR:12-33),median PFS was 6 (95% CI 3.4–8.6),and median OS was 9 (95% CI 5.2–18.1) months. NLR?3.2, PLR?199, and SII?776 were considered as elevated levels. No factor other than NLR could be identified as having an impact on PFS (p=0.015,[HR]:0.46,95%CI: 0.23–0.91). Univariate analyses showed that high baseline NLR, low baseline albumin and CLAS< 2 (0-1) were a significant risk factors for poor OS, but only CLAS<2 was found as an independent prognostic factor for OS in multivariate analyses (p=0.013,[HR]:0.68,95%CI:0.42–0,95). Conclusion: NLR and CLAS were predictive for survival in patients with NSCLC receiving nivolumab.This is the second study on CLAS in the literature. Keywords: Lung Cancer, Nivolumab, Combined LDH Albumin Score (CLAS), Neutrophil-lymphocyte ratio (NLR), Systemic immune-inflammation index (SII)
Cite This Article
Sahin E. Combined LDH Albumin Score (CLAS) and Neutrophil Lymphocyte Ratio (NLR) are Predictive for Survival Patients with Metastatic Non-Small Cell Carcinoma Treated with Nivolumab as Monotherapy. EJMI. 2024; 8(1): 28-34
Corresponding Author: Elif Sahin